{"schema_version":"1.0","type":"article","title":"Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.md","lang":"en","date":"2026-08-19","publish_at":"2026-08-19T08:00:00+08:00","updated_at":"2026-08-19","category":"商業分析系列","topic":"商業分析系列","tags":["Skyrizi","Humira","AbbVie","Psoriasis","Autoimmune","IL-23","ICOTYDE","Biopharma"],"summary":"Skyrizi generated $5.505 billion in Q2 2026, only $74 million below Humira's historic quarterly peak. The real succession test spans efficacy, treatment burden, multi-indication reach and access.","key_points":[],"facts":[],"sections":["01 | Humira is declining, and AbbVie has built another $5.5 billion product","02 | Why can psoriasis support a megablockbuster?","03 | Skyrizi's core advantage: deep clearance with a lower treatment burden","04 | An oral drug has arrived. Does that mean the injectable loses?","05 | The next competitive cycle is more complicated than injection versus pill","Conclusion | The next autoimmune drug king will be decided by the entire treatment experience","References","Disclaimer"],"references":[{"title":"[AbbVie second-quarter 2026 financial results]","source":"","date":"","url":"https://news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Results"},{"title":"[AbbVie first-quarter 2026 financial results]","source":"","date":"","url":"https://news.abbvie.com/2026-04-29-AbbVie-Reports-First-Quarter-2026-Financial-Results"},{"title":"[AbbVie full-year and fourth-quarter 2022 financial results]","source":"","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2022-financial"},{"title":"[Skyrizi U.S. prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s044lbl.pdf"},{"title":"[ICOTYDE U.S. prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf"},{"title":"[Johnson & Johnson announcement of FDA approval for ICOTYDE]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/FDA-approval-of-ICOTYDE-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide/default.aspx"},{"title":"[U.S. adult psoriasis prevalence study]","source":"","date":"","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/"},{"title":"[Cosentyx U.S. prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s098lbl.pdf"},{"title":"[AbbVie completes acquisition of Nimble Therapeutics]","source":"","date":"","url":"https://news.abbvie.com/2025-01-23-AbbVie-Completes-Acquisition-of-Nimble-Therapeutics"},{"title":"[AbbVie June 2026 immunology pipeline presentation filed with the SEC]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_ex99-2.htm"},{"title":"Verification cutoff: August 11, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | Humira's historic quarterly peak and Skyrizi's Q2 2026 revenue are now separated by only $74 million","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-01.png"},{"alt":"Figure 2 | Skyrizi and ICOTYDE use very different regimens, and their label results come from separate trials rather than a head-to-head comparison","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-02.png"},{"alt":"Figure 3 | Depth of response, treatment burden, comorbidity and safety, and patient access jointly determine the next autoimmune leader","url":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-19）。Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?。https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh":"2026-08-19-skyrizi-humira-autoimmune-drug-king.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}